Chemotherapy regimen GOLF induces apoptosis in colon cancer cells through multi-chaperone complex inactivation and increased raf-1 ubiquitin-dependent degradation

The multi-drug combination of oxaliplatin (OXA), 5-Fluorouracil (5-FU) and leucovorin (LF) is currently considered as the gold standard treatment for metastatic colorectal carcinoma. In previous studies, we have studied a chemotherapy regimen containing gemcitabine (GEM), OXA, LF, and 5-FU (named GOLF regimen) that has shown a good safety profile and highly significant anti-tumour activity. In the present study, we have investigated on the anti-tumour mechanisms of GOLF in human colon cancer HT-29 and WiDr cell lines. We have found that GOLF induced growth inhibition that was largely caused by apoptosis differently from other combinations. Moreover, the different drugs composing GOLF were highly synergistic in inducing growth inhibition. Apoptosis induced by GOLF combination was paralleled by PARP cleavage and caspase 9 and 3 activation that were not recorded in the other combinations. An about 85% decrease of the activity of Erk and Akt was found in GOLF-treated cells. These effects were likely due to decreased expression of the upstream activator Raf-1 and of Akt itself, respectively. The intracellular levels of these signalling components can be posttranslationally regulated by ubiquitin-dependent degradation through proteasome. Therefore, we have evaluated the expression of some chaperone components and we have found that GOLF did not affect the expression of both heat shock protein (HSP) 90 and 27 but induced an about 90% increase of HSP70 levels suggesting the inactivation of the multi-chaperone complex. Moreover, an about 4-fold increase of the ubiquitination of Raf-1 was also found and the addition for 12 h of 10 µM proteasome inhibitor lactacystin caused an accumulation of the ubiquitinated isoforms of Raf-1. In conclusions, GOLF was a combination highly synergistic in inducing both growth inhibition and apoptosis of colon cancer cells. These effects likely occurred through the disruption of critical survival pathways and the inactivation of multichaperone complex.

[1]  M. Caraglia,et al.  Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer , 2005, Cancer Chemotherapy and Pharmacology.

[2]  M. Caraglia,et al.  Dendritic Cell-Mediated Cross-Presentation of Antigens Derived from Colon Carcinoma Cells Exposed to a Highly Cytotoxic Multidrug Regimen with Gemcitabine, Oxaliplatin, 5-Fluorouracil, and Leucovorin, Elicits a Powerful Human Antigen-Specific CTL Response with Antitumor Activity in Vitro1 , 2005, The Journal of Immunology.

[3]  D. Green,et al.  Apoptotic Pathways: Ten Minutes to Dead , 2005, Cell.

[4]  S. Fulda,et al.  Targeting apoptosis pathways in cancer therapy. , 2004, Current cancer drug targets.

[5]  A. Abbruzzese,et al.  A novel biweekly multidrug regimen of gemcitabine, oxaliplatin, 5-fluorouracil (5-FU), and folinic acid (FA) in pretreated patients with advanced colorectal carcinoma , 2004, British Journal of Cancer.

[6]  S. Gibson,et al.  Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. , 2004, Current cancer drug targets.

[7]  M. Goetz,et al.  The Hsp90 chaperone complex as a novel target for cancer therapy. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  L. Neckers,et al.  Heat shock protein 90 as a molecular target for cancer therapeutics. , 2003, Cancer cell.

[9]  W. Pratt,et al.  Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery 1 , 2003, Experimental biology and medicine.

[10]  Roland Hustinx,et al.  Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Dariusz Leszczynski,et al.  Non-thermal activation of the hsp27/p38MAPK stress pathway by mobile phone radiation in human endothelial cells: molecular mechanism for cancer- and blood-brain barrier-related effects. , 2002, Differentiation; research in biological diversity.

[12]  G. Milano,et al.  Impact of the oxaliplatin-5 fluorouracil-folinic acid combination on respective intracellular determinants of drug activity , 2002, British Journal of Cancer.

[13]  M. Blagosklonny Hsp-90-associated oncoproteins: multiple targets of geldanamycin and its analogs , 2002, Leukemia.

[14]  S. Faivre,et al.  Etudes précliniques de l'oxaliplatine en polychimiothérapie , 2001 .

[15]  J. Buchner,et al.  Hsp90: Chaperoning signal transduction , 2001, Journal of cellular physiology.

[16]  Jason C. Young,et al.  Hsp90: a specialized but essential protein-folding tool. , 2001, The Journal of cell biology.

[17]  L. del Peso,et al.  Hypoxia Induces the Activation of the Phosphatidylinositol 3-Kinase/Akt Cell Survival Pathway in PC12 Cells , 2001, The Journal of Biological Chemistry.

[18]  D R McKenzie,et al.  Mobile phones, heat shock proteins and cancer. , 2001, Differentiation; research in biological diversity.

[19]  L. Chaudhary,et al.  The cell survival signal Akt is differentially activated by PDGF‐BB, EGF, and FGF‐2 in osteoblastic cells , 2001, Journal of cellular biochemistry.

[20]  J. Mendelsohn,et al.  Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody , 2001, Oncogene.

[21]  S. Kimura,et al.  The MEK1‐ERK MAP kinase pathway and the PI 3‐kinase‐Akt pathway independently mediate anti‐apoptotic signals in HepG2 liver cancer cells , 2001, International journal of cancer.

[22]  Ulf R. Rapp,et al.  Apoptosis Suppression by Raf-1 and MEK1 Requires MEK- and Phosphatidylinositol 3-Kinase-Dependent Signals , 2001, Molecular and Cellular Biology.

[23]  Ming-Tsan Lin,et al.  The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6 , 2001, Oncogene.

[24]  Volker Heinemann,et al.  Gemcitabine: Progress in the Treatment of Pancreatic Cancer , 2000, Oncology.

[25]  S. Mani,et al.  Novel combinations with oxaliplatin. , 2000, Oncology.

[26]  G. Hyland Physics and biology of mobile telephony , 2000, The Lancet.

[27]  Honglin Zhou,et al.  Akt Regulates Cell Survival and Apoptosis at a Postmitochondrial Level , 2000, The Journal of cell biology.

[28]  R. Morimoto,et al.  Role of the heat shock response and molecular chaperones in oncogenesis and cell death. , 2000, Journal of the National Cancer Institute.

[29]  L. Wiseman,et al.  Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. , 2000, Drugs.

[30]  Alexander Varshavsky,et al.  The ubiquitin system. , 1998, Annual review of biochemistry.

[31]  T. Cotter,et al.  Heat shock proteins – modulators of apoptosis in tumour cells , 2000, Leukemia.

[32]  David W. P. Thomas,et al.  Cell biology: Non-thermal heat-shock response to microwaves , 2000, Nature.

[33]  A. Abbruzzese,et al.  Interferon-α induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor , 1999, Cell Death and Differentiation.

[34]  L. Garfinkel,et al.  U.S. cancer incidence, mortality and survival: 1973-1996. , 1999, Statistical bulletin.

[35]  L. Wiseman,et al.  Oxaliplatin: a review of its use in the management of metastatic colorectal cancer. , 1999, Drugs & aging.

[36]  M. Mayer,et al.  Molecular chaperones: The busy life of Hsp90 , 1999, Current Biology.

[37]  G L Johnson,et al.  Organization and regulation of mitogen-activated protein kinase signaling pathways. , 1999, Current opinion in cell biology.

[38]  M. Hidalgo,et al.  Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  J. Berlin,et al.  A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumors , 1998, Investigational New Drugs.

[40]  G. Milano,et al.  Search for the optimal schedule for the oxaliplatin/5-fluorouracil association modulated or not by folinic acid: preclinical data. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  D. D. Hoff Promising new agents for treatment of patients with colorectal cancer. , 1998 .

[42]  A. Varshavsky,et al.  The ubiquitin system. , 1997, Trends in biochemical sciences.

[43]  E. Raymond,et al.  [Oxaliplatin: the first DACH platinum in clinical practice]. , 1997, Bulletin du cancer.

[44]  C. Tournigand,et al.  Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hour continuous infusion in pretreated metastatic colorectal cancer. , 1997, European journal of cancer.

[45]  W. Plunkett,et al.  Gemcitabine: preclinical pharmacology and mechanisms of action. , 1996, Seminars in oncology.

[46]  Marco Lorenzi,et al.  Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. , 1994, Gastroenterology.

[47]  A. Chen,et al.  Antimetabolites , 1992, Cancer chemotherapy and biological response modifiers.

[48]  H. Wieand,et al.  Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  J. Laurie,et al.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  J DeMiguel,et al.  Cancer of the colon , 1973 .

[51]  J. Madden,et al.  CANCER OF THE COLON. , 1964, American journal of surgery.

[52]  E. Raymond,et al.  [Preclinical studies of oxaliplatin in combination chemotherapy]. , 2001, Bulletin du cancer.

[53]  F. Lévi,et al.  Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  F. Roviello,et al.  GEMCITABINE (dFdC), 5-FLUROURACIL (5FU), AND FOLINIC ACID (FA) IN THE TREATMENT OF PATIENTS WITH GASTRO-ENTERIC CARCINOMAS: A CLINICAL AND PHARMACOLOGICAL STUDY. , 2000 .

[55]  E. Raymond,et al.  Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines , 1999, Cancer Chemotherapy and Pharmacology.

[56]  A. Abbruzzese,et al.  Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. , 1999, Cell death and differentiation.

[57]  C. Widmann,et al.  Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. , 1999, Physiological reviews.

[58]  G. Francini,et al.  Gemcitabine (dFdC) affects 5-fluorouracil (5-FU9 pharmacokinetic in cancer patients. , 1999 .

[59]  M. Kahn,et al.  Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  M. Hochstrasser Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. , 1995, Current opinion in cell biology.

[61]  J. Misset,et al.  Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[62]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.